Effect of a new type androgen receptor antagonist, TAS3681, on ligand-independent AR activation through its AR downregulation activity.

被引：5
|
作者：
Kajiwara, Daisuke [1 ]
Minamiguchi, Kazuhisa [1 ]
Seki, Masanao [1 ]
Mizutani, Hiroya [1 ]
Aoyagi, Hiroki [1 ]
Okajima, Shigeo [1 ]
Sasaki, Eiji [1 ]
Utsugi, Teruhiro [1 ]
Iwasawa, Yoshikazu [1 ]
机构：
[1] Taiho Pharmaceut Co Ltd, Tsukuba, Ibaraki, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 02期
关键词：
D O I：
10.1200/jco.2016.34.2_suppl.199
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
199
引用
收藏
页数：1
相关论文
共 7 条
  • [1] TAS3681: New class of androgen receptor antagonist with androgen receptor downregulating activity.
    Minamiguchi, Kazuhisa
    Seki, Masanao
    Aoyagi, Hiroki
    Kajiwara, Daisuke
    Mori, Tomoko
    Masuko, Norio
    Fujita, Ryouto
    Okajima, Shigeo
    Hayashi, Yukio
    Sasaki, Eiji
    Utsugi, Teruhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [2] Biological characterization of TAS3681, a new type of androgen receptor antagonist with androgen receptor downregulating activity
    Minamiguchi, K.
    Seki, M.
    Aoyagi, H.
    Mori, T.
    Kajiwara, D.
    Masuko, N.
    Fujita, R.
    Okajima, S.
    Hayashi, Y.
    Sasaki, E.
    Utsugi, T.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 103 - 103
  • [3] TAS3681, a novel type of AR antagonist with AR downregulating activity, as a new targeted therapy for aberrant AR-driven prostate cancer.
    Seki, Masanao
    Minamiguchi, Kazuhisa
    Kajiwara, Daisuke
    Mizutani, Hiroya
    Yoshida, Shohei
    Sasaki, Eiji
    Utsugi, Teruhiro
    Iwasawa, Yoshikazu
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [4] TAS3681, a new type of androgen receptor antagonist, disrupts aberrant AR signaling that drives tumor resistance to AR-targeted therapies by downregulating full-length and splice variant AR
    Kajiwara, D.
    Minamiguchi, K.
    Seki, M.
    Mizutani, H.
    Yamamura, K.
    Okajima, S.
    Sasaki, E.
    Utsugi, T.
    Iwasawa, Y.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S127 - S127
  • [5] The impact of TAS3681, a new type of androgen receptor antagonist, on aberrant AR signaling that drives tumor resistance to AR-targeted therapies by down-regulating full length and splice variant AR.
    Kajiwara, Daisuke
    Minamiguchi, Kazuhisa
    Seki, Masanao
    Mizutani, Hiroya
    Yamamura, Keisuke
    Okajima, Shigeo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [6] First-in-human study of TAS3681, an oral androgen receptor (AR) antagonist with AR and AR splice variant (AR-SV) downregulation activity, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone (ABI) and/or enzalutamide (ENZ) and chemotherapy (CT).
    De Bono, Johann S.
    Cook, Natalie
    Yu, Evan Y.
    Lara, Primo
    Wang, Judy S.
    Yamasaki, Yoshihiko
    Yamamiya, Ikuo
    Gao, Ping
    Calleja, Elizabeth Martine
    Rathkopf, Dana E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor
    Sugita, S
    Kawashima, H
    Tanaka, T
    Kurisu, T
    Sugimura, K
    Nakatani, T
    ONCOLOGY REPORTS, 2004, 11 (06) : 1273 - 1279
1